Aldeyra falls after FDA extends review of eye disease drug

Shares of Aldeyra Therapeutics ALDX.O fall 15.5% to $3.37 premarket

Co says U.S. FDA has extended the review of its drug reproxalap for treating symptoms of dry eye disease

Says FDA will now give its decision on March 16, 2026, instead of its previous action date of December 16

The FDA has made no other requests and did not identify any other specific issues with the marketing application - ALDX

As of last close, stock down 20% YTD